3+ hour, 43+ min ago  (225+ words) Jun Li further remarked, "Studying previously overlooked populations frequently uncovers biological insights that challenge prevailing assumptions and enrich our comprehension of cancer." By capturing the invisible intricacies of tumor biology in Native American women, this research paves the way for…...

8+ hour, 54+ min ago  (493+ words) A Phase 1b clinical trial of Eli Lilly's gene therapy VERVE-102 has shown up to 62% reduction in LDL cholesterol with a single dose, raising hopes for long-term treatment of hypercholesterolaemia and heart disease risk. A one-time gene therapy for treating hypercholesterolaemia…...

1+ day, 4+ hour ago  (383+ words) A single infusion. A dramatic drop in bad cholesterol. And results that may last a lifetime. An experimental gene-editing treatment is turning heads in the medical world " and researchers say it could one day change the way heart'disease is prevented…...

6+ day, 6+ hour ago  (197+ words) " "Of first 20 patients, all four MRD-negative patients have converted to complete response (CR)" " " "CR rate now 95% (19 of 20 patients)" " " All CRs reached within 1 year of follow-up post-dosing" " " No relapses to-date observed for patients who have reached CR" " " All subsequently enrolled patients…...

6+ hour, 49+ min ago  (278+ words) TAIPEI and SAN MATEO, Calif. , May 27, 2026 (GLOBE NEWSWIRE) -- Precision Medicine Asia, Limited (PREMIA) and Lind today announced the formation of Lind Asia, a strategic joint venture dedicated to revolutionizing clinical trial enrollment in the Asia-Pacific region. Lind Asia will serve…...

16+ hour, 7+ min ago  (101+ words) The Clinical Trial Vanguard Tedopi Plus Pembrolizumab Improves Progression-Free Survival in Ovarian Cancer A hazard ratio of 0. 53 against best supportive care sounds straightforward until you examine the baseline: median progression-free survival in the control arm was just 2. 8 months, reflecting a…...

20+ hour, 13+ min ago  (269+ words) Al-Ola A Abdallah, Associate Professor and Plasma Cell Disorder Program Director of the Division of HMCT at the University of Kansas Medical Center, shared a post on'X: "Dual-Target CAR-T Strikes Hard in EMD: ORR 97%, PFS 6 months! Is Persistence the Missing…...

20+ hour, 2+ min ago  (483+ words) A single infusion of VERVE-102 sharply lowered PCSK9 and LDL cholesterol in a small phase 1 trial, offering early evidence for a potentially durable genetic approach to cholesterol control, while long-term safety and clinical benefit remain to be proven. Study: In Vivo…...

16+ hour, 13+ min ago  (63+ words) Whalesbook Eli Lilly's gene-editing therapy VERVE-102 has shown impressive early results, cutting LDL-C by 62% and PCSK9 protein by 88% in a Phase 1b trial. This one-time treatment, acquired from Verve Therapeutics, aims to offer a permanent solution for high cholesterol patients, reducing the…...

20+ hour, 40+ min ago  (279+ words) In an early-stage clinical trial, published in "The New England Journal of Medicine" and presented at the European Atherosclerosis Society Congress this week, researchers reported that a single infusion of a gene-editing therapy called VERVE-102 sharply lowered LDL cholesterol by…...